-10.1%
QBTS vs MRNA
+154.4%
-164.5%
-46.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | -3.4% | +0.3% | -3.0% |
| 7D | +3.8% | -10.1% | +13.9% | +4.2% |
| 30D | -15.2% | +126.7% | -141.9% | -21.1% |
| 3M | -27.2% | +184.1% | -211.3% | -43.3% |
| 6M | -10.1% | +143.3% | -153.4% | -16.5% |
| All | -10.1% | +154.4% | -164.5% | -16.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling